230 related articles for article (PubMed ID: 32976550)
1. Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses.
Thangavelu G; Wang C; Loschi M; Saha A; Osborn MJ; Furlan SN; Aoyama K; McDonald-Hyman C; Aguilar EG; Janesick AS; Chandraratna RA; Refaeli Y; Panoskaltsis-Mortari A; MacDonald KP; Hill GR; Zeiser R; Maillard I; Serody JS; Murphy WJ; Munn DH; Blumberg B; Brown C; Kuchroo V; Kean LS; Hippen KL; Noelle RJ; Blazar BR
Blood; 2021 Feb; 137(8):1090-1103. PubMed ID: 32976550
[TBL] [Abstract][Full Text] [Related]
2. Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice.
Daenthanasanmak A; Iamsawat S; Chakraborty P; Nguyen HD; Bastian D; Liu C; Mehrotra S; Yu XZ
Blood; 2019 Jan; 133(3):266-279. PubMed ID: 30514750
[TBL] [Abstract][Full Text] [Related]
3. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
Yao Y; Wang L; Zhou J; Zhang X
J Transl Med; 2017 Feb; 15(1):28. PubMed ID: 28183349
[TBL] [Abstract][Full Text] [Related]
4. Curcumin attenuates acute graft-versus-host disease severity via in vivo regulations on Th1, Th17 and regulatory T cells.
Park MJ; Moon SJ; Lee SH; Yang EJ; Min JK; Cho SG; Yang CW; Park SH; Kim HY; Cho ML
PLoS One; 2013; 8(6):e67171. PubMed ID: 23840617
[TBL] [Abstract][Full Text] [Related]
5. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.
Choi J; Ritchey J; Prior JL; Holt M; Shannon WD; Deych E; Piwnica-Worms DR; DiPersio JF
Blood; 2010 Jul; 116(1):129-39. PubMed ID: 20424188
[TBL] [Abstract][Full Text] [Related]
6. Preimplantation factor reduces graft-versus-host disease by regulating immune response and lowering oxidative stress (murine model).
Azar Y; Shainer R; Almogi-Hazan O; Bringer R; Compton SR; Paidas MJ; Barnea ER; Or R
Biol Blood Marrow Transplant; 2013 Apr; 19(4):519-28. PubMed ID: 23266739
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
8. [Influence of mouse genetic engineering regulatory T cells infusion on post-allogeneic bone marrow transplantation acute graft-versus-host disease in mice].
Cao J; Li L; Chen C; Zeng LY; Li ZY; Pan XY; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):83-8. PubMed ID: 21429372
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease.
Le HT; Keslar K; Nguyen QT; Blazar BR; Hamilton BK; Min B
Front Immunol; 2020; 11():181. PubMed ID: 32117306
[TBL] [Abstract][Full Text] [Related]
10. CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity.
Beres AJ; Haribhai D; Chadwick AC; Gonyo PJ; Williams CB; Drobyski WR
J Immunol; 2012 Jul; 189(1):464-74. PubMed ID: 22649199
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models.
Duramad O; Laysang A; Li J; Ishii Y; Namikawa R
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1154-68. PubMed ID: 21145405
[TBL] [Abstract][Full Text] [Related]
12. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect.
Imado T; Iwasaki T; Kuroiwa T; Sano H; Hara H
Transplantation; 2004 Feb; 77(3):391-8. PubMed ID: 14966413
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of Graft-Versus-Host Disease Control Efficacy by Adoptive Transfer of Type 1 Regulatory T Cells in Bone Marrow Transplant Model.
Jeon YW; Lim JY; Im KI; Kim N; Nam YS; Song YJ; Cho SG
Stem Cells Dev; 2019 Jan; 28(2):129-140. PubMed ID: 30381994
[TBL] [Abstract][Full Text] [Related]
14. Recipient type-specific engineered regulatory T cells prevent graft-vs-host disease after allogeneic bone marrow transplantation in mice.
Chen C; Cao J; Zeng L; Li Y; Wang D; Xu K
Transplant Proc; 2011 Jun; 43(5):2041-8. PubMed ID: 21693322
[TBL] [Abstract][Full Text] [Related]
15. Graft-versus-host disease is enhanced by selective CD73 blockade in mice.
Wang L; Fan J; Chen S; Zhang Y; Curiel TJ; Zhang B
PLoS One; 2013; 8(3):e58397. PubMed ID: 23520507
[TBL] [Abstract][Full Text] [Related]
16. IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.
Koenecke C; Lee CW; Thamm K; Föhse L; Schafferus M; Mittrücker HW; Floess S; Huehn J; Ganser A; Förster R; Prinz I
J Immunol; 2012 Sep; 189(6):2890-6. PubMed ID: 22869903
[TBL] [Abstract][Full Text] [Related]
17. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
18. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
[TBL] [Abstract][Full Text] [Related]
19. Recipient-Derived Allo-iTregs Induced by Donor DCs Effectively Inhibit the Proliferation of Donor T Cells and Reduce GVHD.
Yang ZG; Wen RT; Feng JS; Cao PJ; Zhou HT; Liu WX
Anat Rec (Hoboken); 2019 May; 302(5):825-836. PubMed ID: 30312018
[TBL] [Abstract][Full Text] [Related]
20. Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease.
Kim BS; Nishikii H; Baker J; Pierini A; Schneidawind D; Pan Y; Beilhack A; Park CG; Negrin RS
Blood; 2015 Jul; 126(4):546-57. PubMed ID: 26063163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
